Literature DB >> 25144277

Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis.

Marni B Siegel, Amanda E D Van Swearingen, Carey K Anders.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25144277      PMCID： PMC5504407     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  23 in total

Review 1.  Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

Authors:  Nancy U Lin; Jeffrey S Wefel; Eudocia Q Lee; David Schiff; Martin J van den Bent; Riccardo Soffietti; John H Suh; Michael A Vogelbaum; Minesh P Mehta; Janet Dancey; Mark E Linskey; D Ross Camidge; Hidefumi Aoyama; Paul D Brown; Susan M Chang; Steven N Kalkanis; Igor J Barani; Brigitta G Baumert; Laurie E Gaspar; F Stephen Hodi; David R Macdonald; Patrick Y Wen
Journal:  Lancet Oncol       Date:  2013-09       Impact factor: 41.316

Review 2.  Updates on the management of breast cancer brain metastases.

Authors:  Elgene Lim; Nancy U Lin
Journal:  Oncology (Williston Park)       Date:  2014-07       Impact factor: 2.990

Review 3.  New insights and emerging therapies for breast cancer brain metastases.

Authors:  Elgene Lim; Nancy U Lin
Journal:  Oncology (Williston Park)       Date:  2012-07       Impact factor: 2.990

4.  Phase I study of GRN1005 in recurrent malignant glioma.

Authors:  Jan Drappatz; Andrew Brenner; Eric T Wong; April Eichler; David Schiff; Morris D Groves; Tom Mikkelsen; Steve Rosenfeld; John Sarantopoulos; Christina A Meyers; Robert M Fielding; Kelly Elian; Xiaolin Wang; Betty Lawrence; Mona Shing; Stephen Kelsey; Jean Paul Castaigne; Patrick Y Wen
Journal:  Clin Cancer Res       Date:  2013-01-24       Impact factor: 12.531

Review 5.  Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Authors:  Leslie L Muldoon; Carole Soussain; Kristoph Jahnke; Conrad Johanson; Tali Siegal; Quentin R Smith; Walter A Hall; Kullervo Hynynen; Peter D Senter; David M Peereboom; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

6.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

7.  Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.

Authors:  Carey K Anders; Barbara Adamo; Olga Karginova; Allison M Deal; Sumit Rawal; David Darr; Allison Schorzman; Charlene Santos; Ryan Bash; Tal Kafri; Lisa Carey; C Ryan Miller; Charles M Perou; Norman Sharpless; William C Zamboni
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

8.  Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition?

Authors:  Amanda Ed Van Swearingen; Marni B Siegel; Carey K Anders
Journal:  Breast Cancer Res       Date:  2014-05-06       Impact factor: 6.466

9.  Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

Authors:  J-Y Pierga; F-C Bidard; C Cropet; P Tresca; F Dalenc; G Romieu; M Campone; C Mahier Aït-Oukhatar; E Le Rhun; A Gonçalves; M Leheurteur; J Dômont; M Gutierrez; H Curé; J-M Ferrero; C Labbe-Devilliers; T Bachelot
Journal:  Ann Oncol       Date:  2013-09-06       Impact factor: 32.976

10.  Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients.

Authors:  Y H Park; M J Park; S H Ji; S Y Yi; D H Lim; D H Nam; J-I Lee; W Park; D H Choi; S J Huh; J S Ahn; W K Kang; K Park; Y-H Im
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640
View more
  1 in total

1.  Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.

Authors:  Amanda E D Van Swearingen; Maria J Sambade; Marni B Siegel; Shivani Sud; Robert S McNeill; Samantha M Bevill; Xin Chen; Ryan E Bash; Louisa Mounsey; Brian T Golitz; Charlene Santos; Allison Deal; Joel S Parker; Naim Rashid; C Ryan Miller; Gary L Johnson; Carey K Anders
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.